Targeting the CD22 receptor on human B-cell lymphomas with RNA damaging agents.

被引：0
|
作者：
Newton, DL
Mikulski, SM
Sausville, EA
Rybak, SM
机构：
[1] NCI, Frederick Canc Res & Dev Ctr, DCTD, DTP, Frederick, MD 21702 USA
[2] Alfacell Corp, Bloomfield, NJ 07003 USA
来源：
CLINICAL CANCER RESEARCH | 2000年 / 6卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
469
引用
收藏
页码：4560S / 4560S
页数：1
相关论文
共 50 条
  • [41] The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion
    Biberacher, Viola
    Decker, Thomas
    Oelsner, Madlen
    Wagner, Michaela
    Bogner, Christian
    Schmidt, Burkhard
    Kreitman, Robert J.
    Peschel, Christian
    Pastan, Ira
    zum Bueschenfelde, Christian Meyer
    Ringshausen, Ingo
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (05): : 771 - 779
  • [42] Targeting CD79b for Chimeric Antigen Receptor T-Cell Therapy of B-Cell Lymphomas
    Shengnan Ding
    Xia Mao
    Yang Cao
    Na Wang
    Hao Xu
    Jianfeng Zhou
    Targeted Oncology, 2020, 15 : 365 - 375
  • [43] Targeting CD79b for Chimeric Antigen Receptor T-Cell Therapy of B-Cell Lymphomas
    Ding, Shengnan
    Mao, Xia
    Cao, Yang
    Wang, Na
    Xu, Hao
    Zhou, Jianfeng
    TARGETED ONCOLOGY, 2020, 15 (03) : 365 - 375
  • [44] Factors potentially contributing to sensitivities of CD22-targeting agents in B-cell malignancies
    Yao, Xin
    Burke, Patricia
    Obidi, Joyce O.
    Chen, Xiaoru
    Bao, Haifeng
    Yao, Yihong
    Huang, Jiaqi
    CANCER RESEARCH, 2015, 75
  • [45] Efficacy and safety of chimeric antigen receptor T-cell therapy targeting CD19/CD22 in refractory/relapsed transformed aggressive B-cell lymphoma
    Xu, Hao
    Lv, Qiuxia
    Huang, Liang
    Cao, Wenyue
    Wang, Jue
    Meng, Fankai
    Li, Chunrui
    Zheng, Miao
    Chen, Liting
    Mu, Ketao
    Cheng, Jiali
    Zhu, Li
    Zhou, Jianfeng
    Zhang, Yicheng
    Wang, Na
    Cao, Yang
    CYTOTHERAPY, 2023, 25 (02) : 185 - 191
  • [46] STALing B cell responses with CD22
    Chappell, Craig P.
    Clark, Edward A.
    JOURNAL OF CLINICAL INVESTIGATION, 2013, 123 (07): : 2778 - 2780
  • [47] Analysis of murine CD22 during B cell development: CD22 is expressed on B cell progenitors prior to IgM
    Stoddart, A
    Ray, RJ
    Paige, CJ
    INTERNATIONAL IMMUNOLOGY, 1997, 9 (10) : 1571 - 1579
  • [48] Phase I Experience with a Bi-Specific CAR Targeting CD19 and CD22 in Adults with B-Cell Malignancies
    Hossain, Nasheed
    Sahaf, Bita
    Abramian, Matthew
    Spiegel, Jay Y.
    Kong, Katie
    Kim, Stephen
    Mavroukakis, Sharon
    Oak, Jean
    Natkunam, Yasodha
    Meyer, Everett H.
    Frank, Matthew J.
    Feldman, Steven A.
    Long, Steven R.
    Qin, Haiying
    Fry, Terry J.
    Muffly, Lori S.
    Mackall, Crystal L.
    Miklos, David B.
    BLOOD, 2018, 132
  • [49] Epratuzumab modulates B-cell signaling without affecting B-cell numbers or B-cell functions in a mouse model with humanized CD22
    Oezgoer, Lamia
    Brandl, Carolin
    Shock, Anthony
    Nitschke, Lars
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2016, 46 (09) : 2260 - 2272
  • [50] CD19/CD22 CAR-T Cell Cocktail Therapy Following Autologous Transplantation in Patients with Relapsed/Refractory B-Cell Lymphomas
    Cao, Yang
    Xiao, Yi
    Wang, Na
    Wang, Gaoxiang
    Zhou, Xiaoxi
    Huang, Liang
    Chen, Liting
    Xiao, Min
    Zhang, Tongcun
    Zhang, Yicheng
    Zhou, Jianfeng
    BLOOD, 2020, 136
12345